Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by carduon Apr 20, 2011 11:06am
245 Views
Post# 18460802

RE: RE: RE: RE: RE: Over sold

RE: RE: RE: RE: RE: Over sold"Nothing will happen as a result of the Amsterdam Conference. If ONC has material information, fair disclosure laws in both the U.S. and Canada require the company to release immediately in a public forum. Holding material information for months to release it in Amsterdam would be against the law. "

Not necessarily. Correct me if I'm wrong, but isn't the PI of the trial the one who releases the results. The company may not know the results. The PI is a scientist, and within his community he wants the maximum exposure to his trial. Hence possible hedging on early release of positive results to maximize his exposure in his field.

Bullboard Posts